Dostarlimab Yields High cCR Rates and Organ Preservation in Early-Stage dMMR Tumors
OncLive - 09 May 2025Dostarlimab Yields High cCR Rates and Organ Preservation in Early-Stage dMMR Tumors ...
dostarlimab
Dostarlimab Yields High cCR Rates and Organ Preservation in Early-Stage dMMR Tumors ...
FDA Grants Dostarlimab Breakthrough Therapy Designation in dMMR/MSI-H Rectal Cancer
Targeted Oncology - 16 Dec 2024FDA Grants Dostarlimab Breakthrough Therapy Designation in dMMR/MSI-H Rectal Cancer ...
A New Immune Treatment May Work Against Several Cancer Types
Time Magazine - 28 Apr 2025A New Immune Treatment May Work Against Several Cancer Types ...
Jemperli (dostarlimab), MAH: GlaxoSmithKline (Ireland) Limited
European Commission - 08 May 2025Jemperli (dostarlimab), MAH: GlaxoSmithKline (Ireland) Limited ...
Dostarlimab Combo Earns Expanded European Approval in Endometrial Cancer
Cancer Network - 20 Jan 2025Dostarlimab Combo Earns Expanded European Approval in Endometrial Cancer ...
Neoadjuvant dostarlimab averts brutal surgery in 80% of patients with dMMR solid tumors
The Cancer Letter - 02 May 2025Neoadjuvant dostarlimab averts brutal surgery in 80% of patients with dMMR solid tumors ...
Immunotherapy helps certain cancer patients avoid surgery: ‘We hope this is the future’
CNN - 05 May 2025Immunotherapy helps certain cancer patients avoid surgery: ‘We hope this is the future’ ...
Medicine Spares Cancer Patients From Grisly Surgeries and Harsh Therapies
The New York Times - 27 Apr 2025Medicine Spares Cancer Patients From Grisly Surgeries and Harsh Therapies ...
Experimental cancer drugs found to help some patients avoid surgery
The Washington Post - 29 Apr 2025Experimental cancer drugs found to help some patients avoid surgery ...
Neoadjuvant Dostarlimab Eradicates Disease in 82% of Mismatch Repair–Deficient Solid Tumors
OncLive - 28 Apr 2025Neoadjuvant Dostarlimab Eradicates Disease in 82% of Mismatch Repair–Deficient Solid Tumors ...
Dostarlimab-gxly Granted Breakthrough Therapy Designation for Rectal Cancer
Cancer Network - 16 Dec 2024Dostarlimab-gxly Granted Breakthrough Therapy Designation for Rectal Cancer ...
Kelly Spill opted for dostarlimab trial, avoiding rectal cancer treatment that would leave her infertile
The Cancer Letter - 02 May 2025Kelly Spill opted for dostarlimab trial, avoiding rectal cancer treatment that would leave her infertile ...
Real-World Analysis Confirms Efficacy/Safety of Dostarlimab Plus Chemotherapy in Advanced Endometrial Cancer
OncLive - 17 Mar 2025Real-World Analysis Confirms Efficacy/Safety of Dostarlimab Plus Chemotherapy in Advanced Endometrial Cancer ...
Real-World Data Support Dostarlimab Combo Benefit in RUBY Trial
Cancer Network - 20 Mar 2025Real-World Data Support Dostarlimab Combo Benefit in RUBY Trial ...
Dostarlimab/Chemo Improves Long-Term DOR in Advanced Endometrial Cancer
OncLive - 17 Mar 2025Dostarlimab/Chemo Improves Long-Term DOR in Advanced Endometrial Cancer ...
European Commission Approves Dostarlimab Plus Chemo for All Advanced/Recurrent Endometrial Cancer
OncLive - 20 Jan 2025European Commission Approves Dostarlimab Plus Chemo for All Advanced/Recurrent Endometrial Cancer ...
Dr Mirza on Long-Term Response Data for Dostarlimab Plus Chemo in Advanced Endometrial Cancer
OncLive - 26 Mar 2025Dr Mirza on Long-Term Response Data for Dostarlimab Plus Chemo in Advanced Endometrial Cancer ...
Dostarlimab/Chemo Earns Expanded Canadian Approval in Primary Advanced, First Recurrent Endometrial Cancer
OncLive - 18 Apr 2025Dostarlimab/Chemo Earns Expanded Canadian Approval in Primary Advanced, First Recurrent Endometrial Cancer ...
FDA Grants Breakthrough Therapy Designation to Dostarlimab for dMMR/MSI-H Rectal Cancer
OncLive - 18 Dec 2024FDA Grants Breakthrough Therapy Designation to Dostarlimab for dMMR/MSI-H Rectal Cancer ...